Thank you for Subscribing to Life Science Review Weekly Brief
BlueAllele Corporation is the recipient of a patent for advanced gene-editing technology.
Fremont, CA: The United States Patent and Trademark Office has granted United States Patent No. 11,091,756 (the 756 Patent) to BlueAllele Corporation for the use of BlueAllele's PALIDON™ technology.
BlueAlleles PALIDON repair templates have a palindromic, bidirectional structure optimized to take advantage of the high rate of non-homologous end joining (NHEJ) repair found in cells while retaining the capacity to correct damaged mRNA and protein precisely. Due to the compatibility of PALIDON repair templates with existing gene-editing nucleases and delivery systems, PALIDON is particularly well suited for targeting a wide variety of loss-of-function and gain-of-function monogenic disorders.
PALIDON's palindromic design transforms a previously unintended consequence (reverse integration) into a functional event that increases efficacy. By incorporating PALIDON into introns, any potential error induced by the NHEJ pathway can be tolerated, resulting in a reduction in undesirable byproducts. PALIDON captures the endogenous gene's natural expression, allowing for unprecedented control of protein levels and stable, long-lasting modifications.
“We are pleased that the USPTO has recognized the significance of our PALIDON technology and granted
this patent. Protecting intellectual property is a critical part of our business model, particularly as we continue to develop novel and innovative methods for achieving precise gene correction,” said Dr. Nicholas J. Baltes, BlueAlleles chief scientific officer. “Further, the grant of this new patent highlights the unmet need for improving the precision, efficacy and versatility of insertion-based gene editing approaches. As the examiner of the 756 Patent noted, PALIDON expands the field of CRISPR technology in a novel way that was not recognized by prior researchers in this area.”
The 756 Patent comprises claims relating to methods for editing genes with PALIDON. Additionally, the issued claims cover PALIDON's usage in any cell type or system (e.g., animal cells for in vitro or in vivo applications), as well as its use to fix any gene in the genome, offering broad coverage for its use in human therapies.
“This patent demonstrates our expertise and commitment to unlocking the full potential of gene editing for treating genetic diseases,” said Joseph B. Saluri, BlueAlleles chief executive officer. “We are excited to continue advancing our PALIDON platform, along with the other innovative gene correction technologies in our R&D pipeline.”
BlueAllele Corporation is the only owner of the 756 Patent.